Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Purastat for Haemorrhagic Radiation Proctopathy
NCT04918758Completed
- Sponsor
- Manchester University NHS Foundation Trust
- Start
- Jul 2021
- Primary completion
- Dec 2024
- Modality
- Modified Peptides, Hydrogel Systems, Native Peptides
- Countries
- 1
01
Overview
Randomised, open-label trial of PuraStat in radiation proctopathy (2 arms), sponsored by Manchester University NHS Foundation Trust. Primary endpoints: Feasibility to deliver a full randomised controlled trial at 2 years and Safety of endoscopically-delivered Purastat at 2 years. Started Jul 2021; status: completed.
02
Drugs
PuraStat
03
Conditions
radiation proctopathy
Beyond the preview
Go deeper on NCT04918758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04918758.